0000000000061153

AUTHOR

Peter J. Späth

showing 4 related works from this author

Untersuchungen zum hereditären Angioödem im deutschsprachigen Raum

1998

In 6 Zentren der BRD, der Schweiz und Osterreichs wurden 242 Personen erfast, bei denen ein quantitativer und funktioneller Defekt des C1-Esterase-Inhibitors (C1-INH) biochemisch nachgewiesen und uber 2–6 Generationen verfolgt werden konnte. Bezogen auf die Gesamteinwohnerzahl der 3 Lander betragt die Frequenz des HAE auf der Basis der von uns erfasten Falle 0,02×10−4. Da unsere epidemiologischen Untersuchungen nicht flachendeckend erfolgten, ist mit einer um mindestens 1–2 Zehnerpotenzen hoheren Dunkelziffer zu rechnen. Innerhalb eines Kollektivs von 110 Personen mit klinischen Manifestationen eines hereditaren Angioodems (HAE) wurden retrospektiv anamnestische, klinische, Labor- und Thera…

Gynecologymedicine.medical_specialtybusiness.industryMedicineDermatologybusinessC1 esteraseDer Hautarzt
researchProduct

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

2007

In patients with relapsing-remitting multiple sclerosis (MS), IVIG was shown to reduce the relapse rate and progression of disability. In patients with chronic progressive MS, a beneficial effect of IVIG was not documented in placebo controlled studies. This trial investigated the influence of IVIG in primary (PPMS) and secondary (SPMS) chronic progressive MS. Two-hundred and thirty-one patients stratified for PPMS ( n = 34) and SPMS ( n = 197) were randomly assigned to IVIG 0.4 g/kg per month or to placebo for 24 months. Primary endpoints were 1) the time to sustained progression of disease identified as worsening of the expanded disability status scale (EDSS) sustained for 3 months, and …

AdultMalemedicine.medical_specialtyDiseasePlaceboPlacebosCentral nervous system diseaseDisability EvaluationDegenerative diseaseQuality of lifeRecurrencehemic and lymphatic diseasesInternal medicinemedicineHumansImmunologic FactorsProspective StudiesDepression (differential diagnoses)AgedExpanded Disability Status Scalebusiness.industryMultiple sclerosisImmunoglobulins IntravenousMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseSurgeryTreatment OutcomeNeurologyDisease ProgressionFemaleNeurology (clinical)businessMultiple Sclerosis Journal
researchProduct

Hereditary angioedema in children and adolescents - A consensus update on therapeutic strategies for German-speaking countries.

2020

Background/methods At a consensus meeting in August 2018, pediatricians and dermatologists from German-speaking countries discussed the therapeutic strategy for the treatment of pediatric patients with type I and II hereditary angioedema due to C1 inhibitor deficiency (HAE-C1-INH) for Germany, Austria, and Switzerland, taking into account the current marketing approval status. HAE-C1-INH is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema. Diagnosis as early as possible and an optimal management of the disease are important to avoid ineffective therapies and to properly treat swelling attacks. This art…

Adultmedicine.medical_specialtyAdolescentImmunology610610 Medicine & healthLanadelumabDiseaseC1-inhibitorGermanPlasma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIcatibantGermanymedicineHumansImmunology and Allergy030212 general & internal medicineAngioedemaChildIntensive care medicine610 Medicine & healthAngioedemabiologytreatmentbusiness.industryAngioedemas HereditaryC1-INH (C1 inhibitor)medicine.diseaselanguage.human_languagehereditary angioedemapediatric030228 respiratory systemchemistryconsensusPediatrics Perinatology and Child HealthHereditary angioedemalanguagebiology.proteinmedicine.symptombusinessComplement C1 Inhibitor Protein600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und GesundheitRare disease
researchProduct

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, a…

2008

Background We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) in 2004. Objective To ensure that this consensus remains current. Methods In collaboration with the Canadian Network of Rare Blood Disorder Organizations, we held the second Canadian Consensus discussion with our international colleagues in Toronto, Ontario, on February 3, 2006, and reviewed its content at the Fifth C1 Inhibitor Deficiency Workshop in Budapest on June 2, 2007. Papers were presented by international investigators, and this consensus algorithm approach resulted. Results This consensus algorithm …

Pulmonary and Respiratory MedicineConsensus algorithmmedicine.medical_specialtyCanadaC1 inhibitor deficiencyConsensus Development Conferences as TopicInternational CooperationImmunologyMEDLINEEcallantidemedicineImmunology and AllergyHumansHungarybusiness.industryAngioedemas HereditaryState of the art reviewEvidence-based medicinemedicine.diseaseBlood DisorderFamily medicineHereditary angioedemaControlled Clinical Trials as TopicbusinessAlgorithmsmedicine.drugAnnals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology
researchProduct